

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101521 A1

(51) International Patent Classification⁷: **C07D 211/70**,
A61K 31/435, A61P 25/04, 25/22

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-
traZeneca AB, SE-151 85 Södertälje (SE).

(21) International Application Number:
PCT/GB2004/002073

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 13 May 2004 (13.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0301443-8 16 May 2003 (16.05.2003) SE

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except MG, US): **AS-
TRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BROWN, William,
L.** [CA/CA]; AstraZeneca R & D Montreal, 7171 Fredrick-
Banting, St. Laurent, Québec H4S 1Z9 (CA). **GRIFFIN,
Andrew** [GB/CA]; AstraZeneca R & D Montreal, 7171
Fredrick-Banting, St. Laurent, Québec H4S 1Z9 (CA).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF



(I)

(57) Abstract: Compounds of general formula: Formula (I) wherein R¹, R², R³ and R⁴ are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

WO 2004/101521 A1

**DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS
THEREOF AND USES THEREOF**

5 **FIELD OF THE INVENTION**

The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain, anxiety and functional gastrointestinal disorders.

10

BACKGROUND OF THE INVENTION

The receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the δ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the δ receptor have also been shown to possess immunomodulatory activities.

15

The identification of at least three different populations of opioid receptors (μ , δ and κ) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.

20

With few exceptions, currently available selective opioid δ ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic δ -agonist is SNC80 (Bilsky E.J. et al., Journal of Pharmacology and Experimental Therapeutics, 273(1), pp. 359-366 (1995)).

25

Many δ agonist compounds that have been identified in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that many of these δ agonist compounds show significant convulsive effects when administered systemically.

30

U.S. Patent No. 6,187,792 to Delorme et al. describes some δ -agonists. However, there is still a need for improved δ -agonists.

DESCRIPTION OF THE INVENTION

Thus, the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side-effect profile over current μ agonists, as well as having improved systemic efficacy.

5 We have now found certain compounds that exhibit surprisingly improved properties, i.e. improved δ agonist potency, in vivo potency, pharmacokinetic, bioavailability, in vitro stability and/or lower toxicity.

Accordingly, it is an objective of certain embodiments of the present invention to provide improved δ receptor ligands.

10

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979, which is incorporated by references herein for its exemplary chemical structure names and rules on naming chemical structures. Optionally, a name of a compound may be generated using a chemical naming program: ACD/ChemSketch, Version 15 5.09/September 2001, Advanced Chemistry Development, Inc., Toronto, Canada.

The term " C_{m-n} " or " C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

20

The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

25

The term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" general includes both saturated alkyl and unsaturated alkyl.

30

The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to link two structures together.

The term “alkenyl” used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.

5 The term “alkynyl” used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.

The term “cycloalkyl,” used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.

10 The term “cycloalkenyl” used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.

The term “cycloalkynyl” used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

15 The term “aryl” used alone or as suffix or prefix, refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms.

20 The term “arylene” used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link two structures together.

25 The term “heterocycle” used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

30

The term "heteroalkyl" used alone or as a suffix or prefix, refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O and S.

5 The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

10 The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

The term "heterocyclyl" used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.

15 The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.

20 The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character.

The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.

The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.

25 The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

30 A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl,

tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

5 Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more C₁₋₁₂hydrocarbon groups, or one or more chemical groups containing one or more
10 heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include heterocyclyl, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a C₁₋₁₂hydrocarbyl. For example,
15 substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.

The term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure,
20 molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl.

The term "optionally substituted" refers to both groups, structures, or molecules that are substituted and those that are not substituted.

25 Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran,
30 tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4-oxadiazole.

Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrolizidine, and quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-

thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indoliziny, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxaliny, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula $-O-R$, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.

The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula $-NRR'$, wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.

"Acyl" used alone, as a prefix or suffix, means $-C(=O)-R$, wherein R is an optionally substituted hydrocarbyl, hydrogen, amino or alkoxy. Acyl groups include, for example, acetyl, propionyl, benzoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl.

Halogen includes fluorine, chlorine, bromine and iodine.


"Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.

"RT" or "rt" means room temperature.

A first ring group being "fused" with a second ring group means the first ring and the second ring share at least two atoms therebetween.

"Link," "linked," or "linking," unless otherwise specified, means covalently
5 linked or bonded.

In one aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers thereof, enantiomers thereof, and mixtures thereof:



wherein

R^1 is selected from hydrogen, C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{6-10} aryl,
15 optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{6-10} aryl- C_{1-3} alkyl and optionally substituted C_{2-9} heterocyclyl- C_{1-3} alkyl;

R^2 and R^3 are, independently, selected from hydrogen, optionally substituted C_{1-6} alkyl and optionally substituted C_{3-6} cycloalkyl; and

R^4 is selected from optionally substituted C_{3-6} alkyl, optionally substituted C_{3-8} cycloalkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{6-10} aryl- C_{1-6} alkyl, and optionally substituted C_{2-9} heterocyclyl- C_{1-6} alkyl.
20

Particularly, the compounds of the present invention are those of formula I, wherein R¹ is selected from hydrogen, C₁₋₆alkyl-O-C(=O)-, optionally substituted C₁₋₆alkyl, and optionally substituted C₃₋₆cycloalkyl;

R² and R³ are ethyl; and

5 R⁴ is selected from phenyl, C₃₋₅heterocyclyl, phenyl-C₁₋₃alkyl, C₃₋₅heterocyclyl-C₁₋₃alkyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₃alkyl, wherein R⁴ is optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo.

More particularly, the compounds of the present invention are those of
10 formula I, wherein R¹ is selected from hydrogen, C₁₋₆alkyl-O-C(=O)-;

R² and R³ are ethyl; and

R⁴ is selected from phenyl-C₁₋₃alkyl, C₃₋₆cycloalkyl-C₁₋₃alkyl, C₃₋₆cycloalkyl, and phenyl.

Most particularly, the compounds of the present invention are those of formula
15 I, wherein

R¹ is selected from hydrogen and *t*-butyl-O-C(=O)-;

R² and R³ are ethyl; and

R⁴ is selected from phenyl, benzyl, phenethyl, cyclopentyl and cyclohexyl.

It will be understood that when compounds of the present invention contain
20 one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic
25 separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will
30 further be understood that the present invention encompasses tautomers of the compounds of the formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

5 Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable
10 anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic
15 organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

 In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate,
20 tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

 The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.

25 Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation,
30 functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug

addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of the invention for the manufacture of a medicament for the therapy of pain including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

Also within the scope of the invention is the use of any compound of the invention for the manufacture of a medicament for the therapy of anxiety.

Also within the scope of the invention is the use of any of the compounds of the present invention, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound of the present invention, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term
5 "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring
10 conditions and continued therapy for chronic disorders.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally,
15 intrathecally, intracerebroventricularly and by injection into the joints.

In one embodiment of the invention, the route of administration may be orally, intravenously or intramuscularly.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the
20 attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, solvates thereof, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

25 Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, solvates thereof, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain and anxiety.

Further, there is provided a pharmaceutical composition comprising a
30 compound of Formula I, solvates thereof, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

5 A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.

 In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the
10 active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

 For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then
15 poured into convenient sized moulds and allowed to cool and solidify.

 Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

 The term composition is also intended to include the formulation of the active
20 component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

 Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

25 Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

30 Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by


dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

5 Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.

10 A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.


15 In a further aspect, the present invention provides a method of preparing the compounds of the present invention.

In one embodiment, the invention provides a process for preparing a compound of formula I, comprising:



I

20 reacting a compound of formula II with R⁴-X:



wherein

R^1 is selected from C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, and
 5 optionally substituted C_{3-6} cycloalkyl;

R^2 and R^3 are ethyl;

X is selected from Cl, I, Br, OTf and OTs; and

R^4 is selected from phenyl, C_{3-5} heterocyclyl, phenyl- C_{1-3} alkyl,
 C_{3-5} heterocyclyl- C_{1-3} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-3} alkyl, wherein R^4 is
 10 optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated
 C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo.

Particularly, the invention provides a process for preparing a compound of
 formula I as described above, wherein


R^1 is C_{1-6} alkyl-O-C(=O)-;

15 X is selected from Cl, I and Br;


R^2 and R^3 are ethyl; and

R^4 is selected from phenyl- C_{1-3} alkyl, C_{3-6} cycloalkyl- C_{1-3} alkyl, and
 C_{3-6} cycloalkyl.

In a second embodiment, the present invention provides a process for
 20 preparing a compound of formula I, comprising:



reacting a compound of formula III with R^4 -OH:





wherein

R^1 is selected from C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;

R^2 and R^3 are ethyl;

L is selected from $-S(=O)_2-CF_3$,



and $-S(=O)_2-CH_3$; and

R^4 is selected from phenyl, C_{3-5} heterocyclyl, phenyl- C_{1-3} alkyl, C_{3-5} heterocyclyl- C_{1-3} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-3} alkyl, wherein R^4 is

optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo.

Particularly, the invention provides a process for preparing a compound of formula I as described above, wherein

5 R¹ is C₁₋₆alkyl-O-C(=O)-;

 R² and R³ are ethyl;

 L is -S(=O)₂-CF₃; and


 R⁴ is independently selected from phenyl-C₁₋₃alkyl, C₃₋₆cycloalkyl-C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, and C₃₋₆alkyl.

10


More particularly, the compounds of the present invention and intermediates used for the preparation thereof can be prepared according to the synthetic routes as exemplified in Schemes 1-3.

18

Scheme 1




Scheme 2



19

Scheme 3



BIOLOGICAL EVALUATION

The compounds of the invention are found to be active towards δ receptors in warm-blooded animal, e.g., human. Particularly the compounds of the invention are found to be effective δ receptor ligands. *In vitro* assays, *infra*, demonstrate these surprising activities, especially with regard to agonists potency and efficacy as demonstrated in the rat brain functional assay and/or the human δ receptor functional assay (low). This feature may be related to *in vivo* activity and may not be linearly correlated with binding affinity. In these *in vitro* assays, a compound is tested for their activity toward δ receptors and IC_{50} is obtained to determine the selective activity for a particular compound towards δ receptors. In the current context, IC_{50} generally refers to the concentration of the compound at which 50% displacement of a standard radioactive δ receptor ligand has been observed.

The activities of the compound towards κ and μ receptors are also measured in a similar assay.

In vitro modelCell culture

Human 293S cells expressing cloned human κ , δ and μ receptors and neomycin resistance are grown in suspension at 37°C and 5% CO₂ in shaker flasks
5 containing calcium-free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 μ g/ml geneticin.

Rat brains are weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains are homogenized with a polytron for 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride added
10 just prior use to 0.5mM from a 0.5M stock in DMSO:ethanol).

Membrane preparation

Cells are pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec.
15 The suspension is spun at 1000g (max) for 10 min at 4°C. The supernatant is saved on ice and the pellets resuspended and spun as before. The supernatants from both spins are combined and spun at 46,000 g(max) for 30 min. The pellets are resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again. The final pellets are resuspended in membrane buffer (50 mM Tris, 0.32 M sucrose, pH 7.0). Aliquots (1
20 ml) in polypropylene tubes are frozen in dry ice/ethanol and stored at -70°C until use. The protein concentrations are determined by a modified Lowry assay with sodium dodecyl sulfate.

Binding assays

Membranes are thawed at 37°C, cooled on ice, (or kept on ice if not used
25 immediately) passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCl₂, 1 mg/ml BSA (Sigma A-7888), pH 7.4, which is stored at 4°C after filtration through a 0.22 μ m filter, and to which has been freshly added 5 μ g/ml aprotinin, 10 μ M bestatin, 10 μ M diprotin A if the membranes are derived from tissue (rat, mouse, monkey, no DTT). Aliquots of 100 μ l are added to
30 iced 12x75 mm polypropylene tubes containing 100 μ l of the appropriate radioligand

and 100 μ l of test compound at various concentrations. Total (TB) and nonspecific (NS) binding are determined in the absence and presence of 10 μ M naloxone respectively. The tubes are vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum-filtered and washed with about 12 ml/tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM $MgCl_2$) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine. The radioactivity (dpm) retained on the filters is measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid. If the assay is set up in 96-place deep well plates, the filtration is over 96-place PEI-soaked unifilters, which are washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h. The filter plates are counted in a TopCount (Packard) after adding 50 μ l MS-20 scintillation fluid/well. In the case of assays performed in 96 deep well plates, the IC₅₀ of compounds are evaluated from 10-point displacement curves in the case of Delta, and 5-point displacement curves in the case of Mu and Kappa. The assay is done in 300 μ l with the appropriate amount of membrane protein (2 μ g, 35 μ g, and 1 μ g, in the case of Delta, Mu, and Kappa, respectively) and 50000-80000 dpm/well of the appropriate tracer (125I-Deltorphan II, 125I-FK33824, and 125I-DPDYN for Delta, Mu, and Kappa, respectively). The total binding and non-specific binding are determined in absence and presence of 10 μ M of Naloxone.

20 Functional Assays

The agonist activity of the compounds is measured by determining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled. In the GTP binding assay, GTP[γ]³⁵S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat or mouse brain. Agonists stimulate GTP[γ]³⁵S binding in these membranes. The EC₅₀ and E_{max} values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors. For human δ receptor functional assays, EC₅₀ (low) is measured when the human δ receptors used in the assay were expressed at lower levels in comparison with those used in determining EC₅₀ (high). The E_{max} values

were determined in relation to the standard δ agonist SNC80, i.e., higher than 100% is a compound that have better efficacy than SNC80.

Procedure for rat brain GTP

Rat brain membranes are thawed at 37°C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP γ S binding (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl₂, pH 7.4, Add fresh: 1 mM DTT, 0.1% BSA). 120 μ M GDP final is added membranes dilutions. The EC₅₀ and E_{max} of compounds are evaluated from 10-point dose-response curves done in 300 μ l with the appropriate amount of membrane protein (20 μ g/well) and 100000-130000 dpm of GTP γ ³⁵S per well (0.11 -0.14nM). The basal and maximal stimulated binding are determined in absence and presence of 3 μ M SNC-80. The assay performed on HEK 293s cells stably expressing cloned Delta receptors is done in a slightly different buffer (50mM Hepes, 20mM NaOH, 200mM NaCl, 1 mM EDTA, 5mM MgCl₂, pH 7.4, Add fresh: 0.5% BSA, no DTT) and with a 3 μ M final conc. of GDP.

Data analysis

The specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB. Values of IC₅₀ and Hill coefficient (n_H) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GraphPad Prism, SigmaPlot, or ReceptorFit. Values of K_i were calculated from the Cheng-Prussoff equation. Mean \pm S.E.M. values of IC₅₀, K_i and n_H were reported for ligands tested in at least three displacement curves.

Measured using the above described assays, the IC₅₀ towards human δ receptor for most of the compounds of the present invention is generally in the range of 0.31 nM – 1.30 nM. The EC₅₀ and %E_{max} towards human δ receptor for these compounds are generally in the range of 23 nM -70 nM and 94 -115, respectively. The IC₅₀ towards human κ and μ receptors for these compounds is generally in the ranges of 846 nM- 2034 nM and 87 nM – 671 nM, respectively.

Receptor Saturation Experiments

Radioligand K_d values are determined by performing the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K_d (up to 10 times if amounts of radioligand required are feasible). The specific radioligand binding is expressed as pmole/mg membrane protein. Values of K_d and B_{max} from individual experiments are obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one-site model.

Determination Of Mechano-Allodynia Using Von Frey Testing

Testing is performed between 08:00 and 16:00h using the method described by Chaplan et al. (1994). Rats are placed in Plexiglas cages on top of a wire mesh bottom which allows access to the paw, and are left to habituate for 10-15 min. The area tested is the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw is touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, Ill, USA). The von Frey hair is applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, and held for approximately 6-8 seconds. A positive response is noted if the paw is sharply withdrawn. Flinching immediately upon removal of the hair is also considered a positive response. Ambulation is considered an ambiguous response, and in such cases the stimulus is repeated.

Testing Protocol

The animals are tested on postoperative day 1 for the FCA-treated group. The 50% withdrawal threshold is determined using the up-down method of Dixon (1980). Testing is started with the 2.04 g hair, in the middle of the series. Stimuli are always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus is presented; in the event of paw withdrawal, the next weaker stimulus is chosen. Optimal threshold calculation by this method requires 6 responses in the immediate vicinity of the 50% threshold, and counting of these 6 responses begins when the first

change in response occurs, e.g. the threshold is first crossed. In cases where thresholds fall outside the range of stimuli, values of 15.14 (normal sensitivity) or 0.41 (maximally allodynic) are respectively assigned. The resulting pattern of positive and negative responses is tabulated using the convention, X = no withdrawal; O = withdrawal, and the 50% withdrawal threshold is interpolated using the formula:

$$50\% \text{ g threshold} = 10^{(X_f + k\delta)} / 10,000$$

where X_f = value of the last von Frey hair used (log units); k = tabular value (from Chaplan et al. (1994)) for the pattern of positive / negative responses; and δ = mean difference between stimuli (log units). Here $\delta = 0.224$.

- 10 Von Frey thresholds are converted to percent of maximum possible effect (% MPE), according to Chaplan et al. 1994. The following equation is used to compute % MPE:

$$\% \text{ MPE} = \frac{\text{Drug treated threshold (g)} - \text{allodynia threshold (g)}}{\text{Control threshold (g)} - \text{allodynia threshold (g)}} \times 100$$

15 Administration Of Test Substance

Rats are injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varies depending upon the nature of the test compound.

20 Writhing Test

Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.

- 25 A complete and typical Writhing reflex is considered only when the following elements are present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of *both* paws is observable. In this assay, compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1-100 $\mu\text{mol/kg}$.

30 (i) Solutions preparation

Acetic acid (AcOH): 120 μ L of Acetic Acid is added to 19.88 ml of distilled water in order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.

Compound (drug): Each compound is prepared and dissolved in the most suitable vehicle according to standard procedures.

(ii) Solutions administration

The compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing. When the compound is delivered centrally:

Intraventricularly (i.c.v.) or intrathecally (i.t.) a volume of 5 μ L is administered.

The AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the average mice body weight) immediately prior to testing.

(iii) Testing

The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box" cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

For the anxiety and anxiety-like indications, efficacy has been established in the geller-seifter conflict test in the rat.

For the functional gastrointestinal disorder indication, efficacy can be established in the assay described by Coutinho SV *et al*, in American Journal of Physiology - Gastrointestinal & Liver Physiology. 282(2):G307-16, 2002 Feb, in the rat.

ADDITIONAL IN VIVO TESTING PROTOCOLS

Subjects and housing

Naïve male Sprague Dawley rats (175-200g) are housed in groups of 5 in a temperature controlled room (22°C, 40-70% humidity, 12-h light/dark). Experiments are performed during the light phase of the cycle. Animals have food and water ad libitum and are sacrificed immediately after data acquisition.

Sample

Compound (Drug) testing includes groups of rats that do not receive any treatment and others that are treated with E. coli lipopolysaccharide(LPS). For the LPS-treated experiment, four groups are injected with LPS, one of the four groups is then vehicle-treated whilst the other three groups are injected with the drug and its vehicle. A second set of experiments are conducted involving five groups of rats; all of which receive no LPS treatment. The naïve group receives no compound (drug) or vehicle; the other four groups are treated with vehicle with or without drug. These are performed to determine anxiolytic or sedative effects of drugs which can contribute to a reduction in USV.

Administration of LPS

Rats are allowed to habituate in the experimental laboratory for 15-20 min prior to treatment. Inflammation is induced by administration of LPS (endotoxin of gram-negative E. coli bacteria serotype 0111:B4, Sigma). LPS (2.4µg) is injected intracerebro-ventricularly (i.c.v.), in a volume of 10µl, using standard stereotaxic surgical techniques under isoflurane anaesthesia. The skin between the ears is pushed rostrally and a longitudinal incision of about 1cm is made to expose the skull surface. The puncture site is determined by the coordinates: 0.8 mm posterior to the bregma, 1.5 mm lateral (left) to the lambda (sagittal suture), and 5 mm below the surface of the skull (vertical) in the lateral ventricle. LPS is injected via a sterile stainless steel needle (26-G 3/8) of 5 mm long attached to a 100-µl Hamilton syringe by polyethylene tubing (PE20; 10-15 cm). A 4 mm stopper made from a cut needle (20-G) is placed over and secured to the 26-G needle by silicone glue to create the desired 5mm depth.

Following the injection of LPS, the needle remains in place for an additional 10 s to allow diffusion of the compound, then is removed. The incision is closed, and the rat is returned to its original cage and allowed to rest for a minimum of 3.5h prior to testing.

Experimental setup for air-puff stimulation

The rats remains in the experimental laboratory following LPS injection and compound (drug) administration. At the time of testing all rats are removed and

placed outside the laboratory. One rat at a time is brought into the testing laboratory and placed in a clear box ($9 \times 9 \times 18$ cm) which is then placed in a sound-attenuating ventilated cubicle measuring 62(w) \times 35(d) \times 46(h) cm (BRS/LVE, Div. Tech-Serv Inc). The delivery of air-puffs, through an air output nozzle of 0.32 cm, is controlled
5 by a system (AirStim, San Diego Instruments) capable of delivering puffs of air of fixed duration (0.2 s) and fixed intensity with a frequency of 1 puff per 10s. A maximum of 10 puffs are administered, or until vocalisation starts, whichever comes first. The first air puff marks the start of recording.

Experimental setup for and ultrasound recording

10 The vocalisations are recorded for 10 minutes using microphones (G.R.A.S. sound and vibrations, Vedbaek, Denmark) placed inside each cubicle and controlled by LMS (LMS CADA-X 3.5B, Data Acquisition Monitor, Troy, Michigan) software. The frequencies between 0 and 32000Hz are recorded, saved and analysed by the
15 same software (LMS CADA-X 3.5B, Time Data Processing Monitor and UPA (User Programming and Analysis)).

Compounds (Drugs)

All compounds (drugs) are pH-adjusted between 6.5 and 7.5 and administered at a volume of 4 ml/kg. Following compound (drug) administration, animals are returned to their original cages until time of testing.

20 Analysis

The recording is run through a series of statistical and Fourier analyses to filter (between 20-24kHz) and to calculate the parameters of interest. The data are expressed as the mean \pm SEM. Statistical significance is assessed using T-test for comparison between naive and LPS-treated rats, and one way ANOVA followed by
25 Dunnett's multiple comparison test (post-hoc) for drug effectiveness. A difference between groups is considered significant with a minimum p value of ≤ 0.05 . Experiments are repeated a minimum of two times.

Determination of thermal hyperalgesia using the Hargreaves plantar test

Administration of FCA or carrageenan

- Freund's Complete Adjuvant (FCA): SIGMA cat.# F 5881, *Mycobacterium tuberculosis* (H37Ra, ATCC 25177), 1mg/ml, heat killed, dried, 0.85 ml paraffin,
5 0.15 ml mannide monooleate. Or carrageenan Lambda type IV(Cg): SIGMA cat.# C-3889, (Gelatin, vegetable; Irish moss), (1.0% solution) in NaCl.

- 10 Injections are done with a Hamilton syringe with a sterile needle size 26G5/8". Rats are handled and placed in chamber for anaesthesia with isoflurane. When the desired effect is reached, the rat is removed and placed on ventral decubitus (sternal position). The left hind paw is grasped and the needle is introduced subcutaneous, ventral aspect, between footpad of finger # 2 and # 3 in order to reach the middle of the paw (metatarsal area). Finally, a volume of 100µl FCA, or 100µl of carrageenan solution, is slowly injected into the paw, and a small pressure is applied for 3-4 seconds after removal of needles.

- 15 If the animals are waking up during the procedure, they are then return in the inhalation chamber until desired effect is reached.
After the intraplantar injection, the animals are allowed to wake up under observation in their cage.

- 20 For FCA treatment, rats are allowed 48 hours for the development of the inflammatory process. For carrageenan treatment, rats are allowed 3 hours for the development of the inflammatory process. On the morning of the test, rats are placed in the lab (in their cages). They are allowed to habituate to the room for at least 30 minutes.

Test Site

- 25 The heat stimulus is applied to the center of the plantar surface, in between the pads. The test site must be in contact with the glass, with no urine or feces in between, in order to maintain the correct heat transfer properties from the glass to the skin.

- 30 The plantar apparatus consists of a box with a glass top/platform, the glass surface is maintained at 30°C by an internal feedback mechanism. Underneath this glass platform is a light bulb mounted on a moveable arm, a mirror is placed underneath to allow the light to be positioned under the rat's paw. When the light is

activated it shines through an aperture of ~2mm diameter. The experimenter activates the light, and automatic sensors turn the light off when the paw is removed; a cut-off of 20.48 seconds ensures that no tissue damage will occur should the rat fail to remove his paw. The experimenter may also turn off the light at any point. A Timer
5 will record the duration of time that the light is activated.

Flux meter: measures the flux/cm² when the light is activated. This should be maintained at ~97-98; the flux can be modified by adjusting the plantar device, but must never be changed in the middle of an experiment.

Time-Course

10 The experiment can be performed after varying lengths of time following the induction of inflammation. Hyperalgesia is measured at 48h post-FCA injection or 3h post-carrageenan injection.

Test Procedure

Naïve rats: For the procedure of establishing a Dose Response Curve, one group of 7
15 rats is used as a control group; they are anesthetised with the remaining 28 rats, but are not given any injection. Testing of the naïve group may be done either prior to beginning or immediately following the experiment, with the minimum stress possible, the rats are placed in individual Plexiglas boxes (14 x 21 x 9cm) on top of the plantar device; they are allowed to habituate for a period of 30 minutes. When the
20 animals are ready to test, the light is placed directly under the test-site and activated, and the latency to withdrawal is recorded. After a period of 5-8 minutes, to allow skin temperature to return to normal, a second reading is taken, and the rats are then removed and replaced in their cage.

Baseline Values: The remaining 28 rats (divided into 4 groups) that have been
25 injected with FCA (or carrageenan) are placed in individual boxes on the machine and allowed to habituate for 30 minutes. The experimenter should verify the degree of inflammation of the paw and check for discoloration. The heat stimulus is placed under the test site, and the latency to withdrawal is recorded; two readings are taken, as above. It is the comparison of these baseline values with those of the naïve animals
30 that establishes whether hyperalgesia is present.

Post-drug testing: Once hyperalgesia is established, the rats are injected with the compound of interest. Each compound is prepared and dissolved in the most suitable

vehicle according to standard procedures. The administration route, doses, volume, and time of testing after injection is specific for that compound (or class of compounds). When testing compounds at 20-30 minutes post-injection, such as for i.v. or s.c. injections, rats are placed and allowed to habituate on the plantar apparatus while the drug produces its effect. When testing compounds at 60 minutes or more following the injection, rats are placed back in their original cage with their cage mates. Rats are always replaced in their original cages with their original cage mates to minimize the stress of re-establishing a social structure within a group of rats.

30min later rats are placed on the plantar and allowed 30 minutes to habituate to the plantar machine. Testing is performed as described above. Two readings are taken

Criteria for Testing:

The animal must be calm and quiet, yet alert, and in the correct position, with no urine or feces between the skin of the paw and the glass surface of the machine. An animal should not be tested if:

- The animal is in locomotion, including sniffing, grooming and exploring.
- The animal is sleeping.
- The animal is showing obvious signs of stress (tonic immobility, vocalizations, ears flat), unless these are the possible result of a compound side effect and cannot be avoided.
- The animal is positioned in such a way that the paw is not in direct contact with the glass (paw resting on top of tail);
- The animal's paw is displaying blue coloring as a result of a bad injection. In this case, the animal is rejected from the experiment completely (at the beginning).

When urine or feces are present, the animal is removed, the glass surface is wiped clean, and then the animal is replaced. When the animal is sleeping, or exhibiting tonic immobility, the experimenter may gently move the box or move their hand in front of the box to elicit a short-term attentional behaviour. Close observation of the animal's behaviour should be conducted throughout the test.

Re-Tests:

At any time during the experiment, if the experimenter is not certain that the paw withdrawal response was not a response to the heat stimulus, the animal may be

re-tested after 5-8 minutes. This may be due to the animal moving suddenly, or urinating or defecating while the stimulus is being applied.

Acceptable responses:

any of the following are considered responses to the heat stimulus

- 5 -Withdrawal movement of the paw off the glass (often followed by paw licking)
- Lateral movement of the body (contralateral for the stimulated paw)
- Toes are moving off the glass
- the centropalmar (middle paw) aspect of the inflamed paw is removed from the glass.

Analysis

- 10 The data are expressed as the mean \pm SEM. Statistical significance is assessed using T-test for comparison between naive and inflamed rats, and one way ANOVA followed by Dunnett's multiple comparison test (post-hoc) for drug effectiveness. A difference between groups is considered significant with a minimum p value of ≤ 0.05 .

15 EXAMPLES

The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

20

INTERMEDIATE 1

- A mixture of 4-(bromomethyl)benzoic acid, methyl ester (11.2 g, 49 mmol) and trimethyl phosphite (25 mL) was refluxed under N₂ for 5 hrs. Excess trimethyl phosphite was removed by co-distillation with toluene to give INTERMEDIATE 1 in
- 25 quantitative yield. ¹H NMR (CDCl₃) δ 3.20 (d, 2H, J=22 Hz, CH₂), 3.68 (d, 3H 10.8 Hz, OCH₃), 3.78 (d, 3H, 11.2 Hz, OCH₃), 3.91 (s, 3H, OCH₃), 7.38 (m, 2H, Ar-H), 8.00 (d, 2H, J=8 Hz, Ar-H).

- INTERMEDIATE 2: 4-(4-Methoxycarbonyl-benzylidene)-piperidine-1-carboxylic acid *tert*-butyl ester
- 30

To a solution of INTERMEDIATE 1 in dry THF (200 mL) was added dropwise lithium diisopropylamide (32.7 mL 1.5 M in hexanes, 49 mmol) at -78 °C. The reaction mixture was then allowed to warm to room temperature prior to addition of *N*-*tert*-butoxycarbonyl-4-piperidone (9.76 g, 49 mmol in 100 mL dry THF). After 12 hrs, the reaction mixture was quenched with water (300 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic phases were dried over MgSO₄ and evaporated to give a crude product, which was purified by flash chromatography to provide INTERMEDIATE 2 as a white solid (5.64 g, 35%). IR (NaCl) 3424, 2974, 2855, 1718, 1688, 1606, 1427, 1362, 1276 cm⁻¹; ¹H NMR (CDCl₃) δ 1.44 (s, 9H), 2.31 (t, J=5.5 Hz, 2H), 2.42 (t, J=5.5 Hz, 2H), 3.37 (t, J=5.5 Hz, 2H), 3.48 (t, J=5.5 Hz, 2H), 3.87 (s, 3H, OCH₃), 6.33 (s, 1H, CH), 7.20 (d J=6.7 Hz, 2H, Ar-H), 7.94 (d, J=6.7 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 28.3, 29.2, 36.19, 51.9, 123.7, 127.8, 128.7, 129.4, 140.5, 142.1, 154.6, 166.8.

INTERMEDIATE 3: 4-Bromo-4-[bromo-(4-methoxycarbonyl-phenyl)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

To a mixture of INTERMEDIATE 2 (5.2 g, 16 mmol) and K₂CO₃ (1.0 g) in dry dichloromethane (200 mL) was added a solution of bromine (2.9 g, 18 mmol) in 30 mL CH₂Cl₂ at 0 °C. after 1.5 hrs at room temperature, the solution after filtration of K₂CO₃ was condensed. The residue was then dissolved in ethyl acetate (200 mL), washed with water (200 mL), 0.5 M HCl (200 mL) and brine (200 mL), and dried over MgSO₄. Removal of solvents provided a crude product, which was recrystallized from methanol to give INTERMEDIATE 3 as a white solid (6.07 g, 78%). IR (NaCl) 3425, 2969, 1725, 1669, 1426, 1365, 1279, 1243 cm⁻¹; ¹H NMR (CDCl₃) δ 1.28 (s, 9H), 1.75 (m, 1H), 1.90 (m, 1H), 2.1 (m, 2H), 3.08 (br, 2H), 3.90 (s, 3H, OCH₃), 4.08 (br, 3H), 7.57 (d, J=8.4 Hz, 2H, Ar-H) 7.98 (d, J=8.4 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 28.3, 36.6, 38.3, 40.3, 52.1, 63.2, 72.9, 129.0, 130.3, 130.4, 141.9, 154.4, 166.3.

INTERMEDIATE 4: 4-[bromo-(4-carboxy-phenyl)-methylene]-piperidine-1-carboxylic acid *tert*-butyl ester

A solution of INTERMEDIATE 3 (5.4 g 11 mmol) in methanol (300 mL) and 2.0 M NaOH (100 mL) was heated at 40 °C for 3 hrs. The solid was collected by filtration, and dried overnight under vacuum. The dry salt was dissolved in 40% acetonitrile/water, and was adjusted to pH 2 using concentrated HCl.

5 INTERMEDIATE 4 (3.8 g, 87%) was isolated as a white powder by filtration. ¹H NMR (CDCl₃) δ 1.45 (s, 9H, ^tBu), 2.22 (dd, J=5.5 Hz, 6.1 Hz, 2H), 2.64 (dd, J=5.5 Hz, 6.1 Hz, 2H), 3.34 (dd, J=5.5 Hz, 6.1 Hz, 2H), 3.54 (dd, J=5.5 Hz, 6.1 Hz, 2H), 7.35 (d, J=6.7 Hz, 2H, Ar-H), 8.08 (d, J=6.7 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 28.3, 31.5, 34.2, 44.0, 115.3, 128.7, 129.4, 130.2, 137.7, 145.2, 154.6, 170.3.

10

INTERMEDIATE 5: 4-[bromo-(4-diethylcarbamoyl-phenyl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester

To a solution of INTERMEDIATE 4 (1.0 g, 2.5 mmol) in dry dichloromethane (10 mL) at -20 °C was added isobutylchloroformate (450 mg, 3.3 mmol). After 20 min at -20 °C diethylamine (4 mL) was added and the reaction was allowed to warm to room temperature. After 1.5 hrs the solvents were evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine and dried over MgSO₄. Removal of solvents provided a crude product, which was purified by flash chromatography to give INTERMEDIATE 5 as white needles (800 mg, 73%). IR (NaCl) 3051, 2975, 1694, 1633, 1416, 1281, 1168, 1115 cm⁻¹; ¹H NMR (CDCl₃) δ 1.13 (br, 3H, CH₃), 1.22 (br, 3H, CH₃), 1.44 (s, 9H, ^tBu), 2.22 (t, J=5.5 Hz, 2H), 2.62 (t, J=5.5 Hz, 2H), 3.33 (m, 4H), 3.55 (m, 4H), 7.31 (d, J=8.0 Hz, 2H, Ar-H), 7.36 (d, J=8.0 Hz, 2H, Ar-H); ¹³C NMR (CDCl₃) δ 12.71, 14.13, 28.3, 31.5, 34.2, 39.1, 43.2, 79.7, 115.9, 126.3, 129.3, 136.8, 137.1, 140.6, 154.6, 170.5.

25


INTERMEDIATE 6: *tert*-butyl 4-[(4-[(diethylamino)carbonyl]phenyl)(3-hydroxyphenyl)methylene]piperidine-1-carboxylate

To a flask containing INTERMEDIATE 5 (4.08 g, 9.04 mmol) was added toluene (100 mL), ethanol (100 mL), 3-hydroxyphenylboronic acid (1.97 g, 14.3 mmol), and aqueous 2N sodium carbonate (11.3 mL, 22.6 mmol). The solution was degassed for 20 minutes, then palladium tetrakis(triphenyl)phosphine (1.05 g, 0.909

30

mmol) was added. The reaction mixture was purged with nitrogen and heated to 90 °C. After 5 h, the reaction was cooled to rt and saturated aqueous ammonium chloride was added. The mixture was extracted with two portions of ethyl acetate and the combined organic extracts were dried (Na₂SO₄), filtered and concentrated. The residue was purified by flash chromatography, eluting 0% to 100% ethyl acetate in hexanes, to yield INTERMEDIATE 6 as a colourless solid (4.24 g, 100%). ¹H NMR (400MHz, CDCl₃) δ 1.10 (t, J = 7.42 Hz, 3H), 1.20 (t, J = 7.03 Hz, 3H), 1.42 (s, 9H), 2.25-2.33 (m, 4H), 3.23-3.31 (m, 2H), 3.39-3.46 (m, 4H), 3.46-3.54 (m, 2H), 6.51 (dd, J = 2.15, 1.56 Hz, 1H), 6.57 (ddd, J = 7.62, 1.56, 0.98 Hz, 1H), 6.62 (ddd, J = 8.20, 2.54, 0.98 Hz, 1H), 7.06-7.12 (m, 1H), 7.19 (d, J = 8.40 Hz, 2H), 7.29 (d, J = 8.40 Hz, 2H).

COMPOUND 1: 4-[[3-(benzyloxy)phenyl](piperidin-4-ylidene)methyl]-N,N-diethylbenzamide




15

To a solution of INTERMEDIATE 6 (0.100 g, 0.215 mmol) in dry DMF was added benzylbromide (50 µL, 0.42 mmol) and potassium carbonate (0.150 g, 1.09 mmol). The reaction was heated to 80 °C and stirred for 24 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and washed with two portions of 1M HCl then brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was dissolved in CH₂Cl₂ and trifluoroacetic acid (1 mL) was added. After 2 h, the reaction was concentrated and the residue purified by reverse phase chromatography, eluting 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as the trifluoroacetic acid salt and was lyophilized to give COMPOUND 1 (62 mg, 51%) as a colourless solid. Purity (HPLC): >99% (215 nm), >99% (254 nm), >99% (280 nm); ¹H NMR (400MHz, CD₃OD) δ 1.12 (br t, J = 7.03 Hz, 3H), 1.24 (br t, J = 7.03 Hz, 3H), 2.49-2.60 (m, 4H), 3.15-3.21 (m, 2H), 3.20-3.26 (m, 2H), 3.25-3.35 (m, 2H), 3.48-3.59 (m,

25


2H), 5.06 (s, 2H), 6.70-6.77 (m, 2H), 6.90-6.96 (m, 1H), 7.24 (d, $J = 8.40$ Hz, 2H), 7.26-7.41 (m, 8 H). Found: C, 59.06; H, 5.54; N, 8.25.

COMPOUND 2: *N,N*-diethyl-4-[[3-(2-phenylethoxy)phenyl](piperidin-4-ylidene)methyl]benzamide



Using the procedure described for COMPOUND 1 with INTERMEDIATE 6 (0.146 g, 0.314 mmol) and 2-bromoethylbenzene (86 μ L, 0.63 mmol) provided COMPOUND 2 (60 mg, 36%) as a colourless solid. Purity (HPLC): >99% (215 nm), >99% (254 nm), >99% (280 nm); ^1H NMR (400MHz, CD_3OD) δ 1.10 (br t, $J = 6.83$ Hz, 3H), 1.23 (br t, $J = 6.83$ Hz, 3H), 2.54-2.60 (m, 4H), 3.02 (t, $J = 6.83$ Hz, 2H), 3.20-3.33 (m, 6H), 3.48-3.58 (m, 2H), 4.13 (t, $J = 6.93$ Hz, 2H), 6.65 (dd, $J = 2.34$, 1.56 Hz, 1H), 6.74 (ddd, $J = 7.62$, 1.56, 0.98 Hz, 1H), 6.84 (ddd, $J = 8.20$, 2.54, 0.59 Hz, 1H), 7.16-7.30 (m, 8H), 7.35 (d, $J = 8.40$ Hz, 2H).


COMPOUND 3: 4-[[3-(cyclopentyloxy)phenyl](piperidin-4-ylidene)methyl]-*N,N*-diethylbenzamide



Using the procedure described for COMPOUND 1 with INTERMEDIATE 6 (0.200 g, 0.430 mmol) and cyclopentyl bromide (92 μ L, 0.86 mmol) provided COMPOUND 3 (78 mg, 33%) as a colourless solid. Purity (HPLC): >99% (215 nm), >99% (254 nm), >99% (280 nm); ^1H NMR (400MHz, CD_3OD) δ 1.12 (br t, $J = 7.23$ Hz, 3H), 1.23 (br t, $J = 7.23$ Hz, 3H), 1.53-1.67 (m, 2H), 1.68-1.81 (m, 4H), 1.80-1.95

(m, 2H), 2.54-2.63 (m, 4H), 3.21-3.35 (m, 6H), 3.48-3.58 (m, 2H), 4.71-4.78 (m, 1H), 6.62 (dd, $J = 2.34, 1.76$ Hz, 1H), 6.71 (ddd, $J = 7.42, 1.37, 0.98$ Hz, 1H), 6.80 (ddd, $J = 8.40, 2.34, 0.78$ Hz, 1H), 7.19-7.29 (m, 3H), 7.36 (d, $J = 8.40$ Hz, 2H). Found: C, 62.54; H, 6.54; N, 4.73. $C_{28}H_{36}N_2O_2 \times 1.3 CF_3CO_2H \times 0.4 H_2O$ has C, 62.50; H, 6.53; N, 4.76%.

COMPOUND 4: 4-[[3-(cyclohexyloxy)phenyl](piperidin-4-ylidene)methyl]-*N,N*-diethylbenzamide



Using the procedure described for COMPOUND 1 with INTERMEDIATE 6 (0.332 g, 0.715 mmol) and cyclohexyl bromide (0.10 mL, 0.81 mmol) provided COMPOUND 4 (168 mg, 42%) as a colourless solid. Purity (HPLC): >96% (215 nm), >99% (254 nm), >99% (280 nm); 1H NMR (400MHz, CD_3OD) δ 1.12 (t, $J = 6.83$ Hz, 3H), 1.23 (t, $J = 6.83$ Hz, 3H), 1.28-1.52 (m, 5H), 1.52-1.61 (m, 1H), 1.71-1.81 (m, 2H), 1.87-1.96 (m, 2H), 2.55-2.63 (m, 4H), 3.21-3.34 (m, 6H), 3.49-3.58 (m, 2H), 4.21-4.31 (m, 1H), 6.65 (dd, $J = 2.34, 1.76$ Hz, 1H), 6.72 (ddd, $J = 7.62, 1.37, 0.98$ Hz, 1H), 6.83 (ddd, $J = 8.40, 2.54, 0.78$ Hz, 1H), 7.20-7.29 (m, 3H), 7.36 (d, $J = 8.40$ Hz, 2H).

INTERMEDIATE 7: *tert*-butyl 4-[[4-[(diethylamino)carbonyl]phenyl}{3-[(trifluoromethyl)sulfonyl]oxy}phenyl)methylene]piperidine-1-carboxylate


To a solution of INTERMEDIATE 6 (1.95 g, 4.20 mmol) and triethylamine (3.00 mL, 21.5 mmol) in dichloromethane (15 mL) was added trifluoromethanesulfonic anhydride (0.95 mL, 5.65 mmol) dropwise at 0 °C. The reaction was allowed to warm to room temperature and was stirred for 15 hours. The solution was diluted with dichloromethane and was washed with two portions of saturated aqueous ammonium chloride, then dried (Na_2SO_4), filtered and concentrated. The residue was purified by flash chromatography, eluting 20% to 50%

ethyl acetate in hexanes to yield INTERMEDIATE 7 (2.00 g, 80%) as a yellow foam.

^1H NMR (400MHz, CDCl_3) δ 1.08-1.18 (m, 3H), 1.20-1.29 (m, 3H), 1.47 (s, 9H), 2.29-2.38 (m, 4H), 3.23-3.34 (m, 2H), 3.44-3.50 (m, 4H), 3.50-3.60 (m, 2H), 7.02-7.05 (m, 1H), 7.09-7.18 (m, 4H), 7.34 (d, $J = 8.01$ Hz, 2H), 7.36-7.41 (m, 1H).

5


COMPOUND 5: *N,N*-diethyl-4-[(3-phenoxyphenyl)(piperidin-4-ylidene)methyl]benzamide



An oven-dried 2-necked round bottom flask equipped with a reflux condenser was charged with $\text{Pd}_2(\text{dba})_3$ (7.5 mg, 0.008 mmol), 2-(di-*t*-butylphosphino)biphenyl (5.5 mg, 0.018 mmol), K_3PO_4 (77 mg, 0.36 mmol), and phenol (19 mg, 0.20 mmol). The flask was fitted with a rubber septum, purged with nitrogen, and then a solution of INTERMEDIATE 7 (100 mg, 0.168 mmol) in degassed toluene (2 mL) was added through the septum. The reaction was heated to 80 °C and stirred for 22 h. The flask was cooled to room temperature and the mixture was absorbed onto silica gel. Flash chromatography, eluting 20% to 50% ethyl acetate in hexanes afforded the BOC-protected derivative (50 mg, 0.093 mmol) as a yellow oil. The oil was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (0.5 mL) was added. After 4 h, the solution was concentrated and purified by reverse phase chromatography, eluting 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as the trifluoroacetic acid salt and was lyophilized to give COMPOUND 5 (44 mg, 47%) as a white solid. Purity (HPLC): >99% (215 nm), >99% (254 nm), >99% (280 nm); ^1H NMR (400MHz, CD_3OD) δ 1.12 (br t, $J = 7.03$ Hz, 3H), 1.23 (br t, $J = 6.83$ Hz, 3H), 2.54-2.63 (m, 4H), 3.20-3.26 (m, 4H), 3.26-3.34 (m, 2H), 3.49-3.58 (m, 2H), 6.75-6.78 (m, 1H), 6.86-6.99 (m, 4H), 7.07-7.14 (m, 1H), 7.25 (d, $J = 8.40$ Hz, 2H), 7.30-7.38 (m, 5H). Found: C, 62.49; H, 5.74; N, 4.59. $\text{C}_{29}\text{H}_{32}\text{N}_2\text{O}_2 \times 1.4 \text{ CF}_3\text{CO}_2\text{H} \times 0.6 \text{ H}_2\text{O}$ has C, 62.51; H, 5.71; N, 4.58%.

What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

**I**

wherein

R^1 is selected from hydrogen, C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{6-10} aryl- C_{1-3} alkyl and optionally substituted C_{2-9} heterocyclyl- C_{1-3} alkyl;

R^2 and R^3 are, independently, selected from hydrogen, optionally substituted C_{1-6} alkyl and optionally substituted C_{3-6} cycloalkyl; and

R^4 is selected from optionally substituted C_{3-6} alkyl, optionally substituted C_{3-8} cycloalkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{6-10} aryl- C_{1-6} alkyl, and optionally substituted C_{2-9} heterocyclyl- C_{1-6} alkyl.

2. A compound according to claim 1,

wherein R^1 is selected from hydrogen, C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;


R^2 and R^3 are ethyl; and

R^4 is selected from phenyl, C_{3-5} heterocyclyl, phenyl- C_{1-3} alkyl, C_{3-5} heterocyclyl- C_{1-3} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-3} alkyl, wherein R^4 is


optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo.

3. A compound according to claim 1,
5 wherein R¹ is selected from hydrogen, C₁₋₆alkyl-O-C(=O)-;
R² and R³ are ethyl; and
R⁴ is selected from phenyl-C₁₋₃alkyl, C₃₋₆cycloalkyl-C₁₋₃alkyl, C₃₋₆cycloalkyl,
and phenyl.
- 10 4. A compound according to claim 1, wherein
R¹ is selected from hydrogen and *t*-butyl-O-C(=O)-;
R² and R³ are ethyl; and
R⁴ is selected from phenyl, benzyl, phenethyl, cyclopentyl and cyclohexyl.
- 15 5. A compound selected from:
4-[[3-(benzyloxy)phenyl](piperidin-4-ylidene)methyl]-*N,N*-diethylbenzamide;
N,N-diethyl-4-[[3-(2-phenylethoxy)phenyl](piperidin-4-
ylidene)methyl]benzamide;
4-[[3-(cyclopentyloxy)phenyl](piperidin-4-ylidene)methyl]-*N,N*-
20 diethylbenzamide;
4-[[3-(cyclohexyloxy)phenyl](piperidin-4-ylidene)methyl]-*N,N*-
diethylbenzamide;
N,N-diethyl-4-[(3-phenoxyphenyl)(piperidin-4-ylidene)methyl]benzamide;
and pharmaceutically acceptable salts thereof.
- 25 6. A compound according to any one of claims 1-5 for use as a medicament.
7. The use of a compound according to any one of claims 1-5 in the manufacture
of a medicament for the therapy of pain, anxiety or functional gastrointestinal
30 disorders.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
9. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
10. A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
11. A process for preparing a compound of formula I, comprising:

**I**

reacting a compound of formula II with R⁴-X:

**II**

41

wherein

R^1 is selected from C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;


R^2 and R^3 are ethyl;

5 X is selected from Cl, I, Br, OTf and OTs; and

R^4 is selected from phenyl, C_{3-5} heterocyclyl, phenyl- C_{1-3} alkyl, C_{3-5} heterocyclyl- C_{1-3} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-3} alkyl, wherein R^4 is optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo.

10


12. A process for preparing a compound of formula I, comprising:



I

reacting a compound of formula III with R^4 -OH:

15



III



wherein

42

R^1 is selected from C_{1-6} alkyl-O-C(=O)-, optionally substituted C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;

R^2 and R^3 are ethyl;

L is selected from $-S(=O)_2-CF_3$,



and $-S(=O)_2-CH_3$; and

R^4 is selected from phenyl, C_{3-5} heterocyclyl, phenyl- C_{1-3} alkyl, C_{3-5} heterocyclyl- C_{1-3} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-3} alkyl, wherein R^4 is optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo.

INTERNATIONAL SEARCH REPORT

national Application No

T/GB2004/002073

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/70 A61K31/435 A61P25/04 A61P25/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/28275 A (WEI ZHONGYONG ; DELORME DANIEL (CA); ROBERTS EDWARD (CA); ASTRA PHARMA) 2 July 1998 (1998-07-02) claim 1; examples 21-23	1-12
Y	WO 02/094810 A (WALPOLE CHRISTOPHER ; BROWN WILLIAM (CA); WEI ZHONGYONG (CA); ASTRAZEN) 28 November 2002 (2002-11-28) claims 1,8-13	1-12
Y	WO 01/74804 A (WALPOLE CHRISTOPHER ; BROWN WILLIAM (CA); ASTRAZENECA AB (SE)) 11 October 2001 (2001-10-11) claims 1,8-17	1-12
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

20 September 2004

Date of mailing of the international search report

28/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

vanVoorst tot Voorst, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/002073

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ZHANG X ET AL: "PROBES FOR NARCOTIC RECEPTOR MEDIATED PHENOMENA. 26.1-3 SYNTHESIS AND BIOLOGICAL EVALUATION OF DIARYLMETHYLPIPERAZINES AND DIARYLMETHYLPIPRIDINES AS NOVEL, NONPEPTIDIC DELTA OPIOID RECEPTOR LIGANDS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 26, 1999, pages 5455-5463, XP002943072 ISSN: 0022-2623 page 5455; compounds 6A,6B -----</p>	1-12

INTERNATIONAL SEARCH REPORT

international application No.
PCT/GB2004/002073

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9, 10
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 9 and 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002073

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9828275	A	02-07-1998	AU 737999 B2	06-09-2001
			AU 5351298 A	17-07-1998
			BR 9714055 A	09-05-2000
			CA 2274074 A1	02-07-1998
			CN 1246111 A	01-03-2000
			CZ 9902199 A3	17-11-1999
			EE 9900256 A	15-12-1999
			EP 0946511 A1	06-10-1999
			ID 22074 A	02-09-1999
			JP 2001507350 T	05-06-2001
			NO 993022 A	20-08-1999
			NZ 336029 A	30-03-2001
			PL 334374 A1	28-02-2000
			RU 2193029 C2	20-11-2002
			WO 9828275 A1	02-07-1998
			SK 76299 A3	08-11-1999
			TR 9901417 T2	21-10-1999
			TW 548271 B	21-08-2003
			US 6187792 B1	13-02-2001
			US 2003149023 A1	07-08-2003
			US 2004171612 A1	02-09-2004
			US 2001021715 A1	13-09-2001
			ZA 9711059 A	22-06-1998
			HU 0000610 A2	28-09-2000
WO 02094810	A	28-11-2002	BR 0209667 A	20-04-2004
			CA 2446331 A1	28-11-2002
			CZ 20033087 A3	12-05-2004
			EE 200300543 A	16-02-2004
			EP 1395574 A1	10-03-2004
			WO 02094810 A1	28-11-2002
			SK 13932003 A3	04-05-2004
			US 2004138259 A1	15-07-2004
WO 0174804	A	11-10-2001	AT 269324 T	15-07-2004
			AU 4498101 A	15-10-2001
			BR 0109816 A	21-01-2003
			CA 2404386 A1	11-10-2001
			CN 1432009 T	23-07-2003
			CZ 20023289 A3	12-03-2003
			DE 60103889 D1	22-07-2004
			EE 200200571 A	15-04-2004
			EP 1282616 A1	12-02-2003
			HU 0300427 A2	28-06-2003
			JP 2003529596 T	07-10-2003
			NO 20024775 A	03-12-2002
			NZ 522142 A	25-06-2004
			PL 357780 A1	26-07-2004
			WO 0174804 A1	11-10-2001
			SK 14232002 A3	03-06-2003
			US 2003187022 A1	02-10-2003